At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses a phase 1b trial that was designed to evaluate the safety and antitumour activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, combined with tremelimumab, an anti-CTLA-4 antibody, in patients with stage III/IV non-small cell lung cancer (NSCLC).
Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer
25th May 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now